Trial Profile
A randomised, open-label, multicentre phase Ib trial evaluating the HCV E1E2-MF59 vaccine in patients with genotype 1a/1b chronic hepatitis C treated with Peg-IFNα2a and ribavirin
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2015
Price :
$35
*
At a glance
- Drugs HCV E1E2MF59 (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 09 Nov 2015 New trial record